Fast Five Quiz: Osteoporosis Prevention and Treatment

Herbert S. Diamond, MD


December 10, 2020

According to guidelines from the American College of Physicians, pharmacologic treatment should be offered to all women with known osteoporosis to reduce the risk for hip and vertebral fractures. Treatment options include alendronate, risedronate, zoledronic acid, or denosumab.

Estrogen or estrogen plus progestogen or raloxifene should not be used for the treatment of osteoporosis in postmenopausal women owing to the risk for potentially adverse outcomes. Selective estrogen receptor modulators can be considered.

Bisphosphonates are the most frequently used agents for osteoporosis. According to guidelines from the American Association of Clinical Endocrinologists, in patients with high fracture risk, a bisphosphonate holiday should be considered after 6-10 years of treatment. For patients who are not at high risk for fracture, a holiday may be considered after 5 years of use.

Learn more about the treatment of osteoporosis.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.